发布求助
文献互助 智能选刊 最新文献

Pharmaceutical patent analyst最新文献

筛选
英文 中文
Patenting trends by Mexican pharmaceutical companies. 墨西哥制药公司的专利申请趋势。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-11-01 Epub Date: 2024-01-10 DOI: 10.4155/ppa-2023-0029
Luis Villafaña-Diaz, Juan C Perez-Garcia, Diana Barron-Villaverde, Martin Perez-Santos
{"title":"Patenting trends by Mexican pharmaceutical companies.","authors":"Luis Villafaña-Diaz, Juan C Perez-Garcia, Diana Barron-Villaverde, Martin Perez-Santos","doi":"10.4155/ppa-2023-0029","DOIUrl":"10.4155/ppa-2023-0029","url":null,"abstract":"<p><p><b>Aim:</b> the activity of patent claims by Mexican pharmaceutical companies is unknown. <b>Objective:</b> analyse the trend in patents of Mexican pharmaceutical companies. <b>Method:</b> a search for patents was carried out in the patent database of the Mexican Institute of Industrial Property, using the list of Mexican pharmaceutical companies belonging to the Mexican Association of Pharmaceutical Research Industries, and the codes A61K, A61P and C07 of the International Patent Classification. <b>Results:</b> the leading companies in patent applications were Liomont, Senosiain and RIMSA; however, Mexican pharmaceutical companies claim very few patents, only 266 patent applications in the period 2000-2020, with a technological factor with a value of zero, and a commercial factor of little value. <b>Conclusion:</b> Mexican pharmaceutical companies lack a robust patent system, without growth, and with a low percentage of patents with high commercial value.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"275-286"},"PeriodicalIF":1.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipid-based mesoporous silica nanoparticles: a paradigm shift in management of pancreatic cancer. 基于脂质的介孔二氧化硅纳米粒子：胰腺癌治疗模式的转变。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-11-01 Epub Date: 2024-01-12 DOI: 10.4155/ppa-2023-0024
Kiran Kumar Bellapu, Ramesh Joga, Bharthi R Kannan, Sravani Yerram, Priya Varpe, Tejaswini Mergu, Pavan Y Vasu, Saurabh Srivastava, Sandeep Kumar
{"title":"Lipid-based mesoporous silica nanoparticles: a paradigm shift in management of pancreatic cancer.","authors":"Kiran Kumar Bellapu, Ramesh Joga, Bharthi R Kannan, Sravani Yerram, Priya Varpe, Tejaswini Mergu, Pavan Y Vasu, Saurabh Srivastava, Sandeep Kumar","doi":"10.4155/ppa-2023-0024","DOIUrl":"10.4155/ppa-2023-0024","url":null,"abstract":"<p><p>Pancreatic adenocarcinoma, a devastating disease, has the worst cancer prognosis in humans. It often develops resistance to common chemotherapy medications, such as gemcitabine, taxol and 5-fluorouracil. The dense stroma limits therapeutic efficacy in treating this disease. Low or limited drug loading capacity is another problem with current chemotherapeutic agents. There is a need to develop novel approaches to overcome these issues. Hence, an innovative approach has been proposed to co-deliver both hydrophilic (Gemcitabine) and hydrophobic (Paclitaxel) drugs in a single carrier using lipid bilayer-mesoporous silica nanoparticles (LB-MSNP). MSNPs offer effective drug delivery due to their superior bioavailability and physicochemical properties. Further, in order to achieve clinical translation and regulatory approval, toxicity and biodegradability of MSNPs must be resolved.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"261-273"},"PeriodicalIF":1.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139425271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prominence of bioresponsive DNA nanococoons in tackling post-surgery cancer recurrence. 生物反应性DNA纳米茧在治疗术后癌症复发中的突出作用。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-09-01 Epub Date: 2023-11-20 DOI: 10.4155/ppa-2023-0013
Sravani Yerram, Ramesh Joga, Pooja Shende, Priya Varpe, Kiran Kumar Bellapu, Sandeep Kumar
{"title":"Prominence of bioresponsive DNA nanococoons in tackling post-surgery cancer recurrence.","authors":"Sravani Yerram, Ramesh Joga, Pooja Shende, Priya Varpe, Kiran Kumar Bellapu, Sandeep Kumar","doi":"10.4155/ppa-2023-0013","DOIUrl":"10.4155/ppa-2023-0013","url":null,"abstract":"<p><p>Post-surgery cancer recurrence is one of the reasons for increased cancer cases. The effective usage of the enhanced permeability and retention effect of a nanocarrier infused with the bioresponsive release mechanism of checkpoint inhibitors (aPD1 and aCTLA4) can become a boon to mankind. DNA nanococoons (DNCs) comprising cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG-ODNs) with potent immunostimulatory effects can significantly enhance anti-cancer activity. Triglycerylmonostearate (TGMS) with enzymatic cleavage potential at the wound sites of tumor resection, upon caging with restriction enzyme (HhaI) followed by attaching to DNCs, makes the immunotherapy bioresponsive. Hhal-TGMS-DNCs-aPD1 triggered by the inflammation at the wound site undergoes enzymatic cleavage, releases the restriction enzyme, converts DNCs to CpG ODNs sequentially and with sustained aPD1 release exerts an appreciable anti-cancer effect.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"219-229"},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Steroid sulfatase inhibitors and sulfated C19 steroids for proteotoxicity-related diseases: a patent spotlight. 类固醇磺化酶抑制剂和硫酸C19类固醇治疗蛋白质毒性相关疾病:专利焦点
IF 1.8
Pharmaceutical patent analyst Pub Date : 2023-09-01 Epub Date: 2023-11-20 DOI: 10.4155/ppa-2023-0010
Rami A Al-Horani
{"title":"Steroid sulfatase inhibitors and sulfated C19 steroids for proteotoxicity-related diseases: a patent spotlight.","authors":"Rami A Al-Horani","doi":"10.4155/ppa-2023-0010","DOIUrl":"10.4155/ppa-2023-0010","url":null,"abstract":"<p><p>Aging and proteotoxicity go hand in hand. Inhibiting proteotoxicity has been proposed to extend lifespan. This invention describes a new strategy to limit proteotoxicity and to extend the lifespan. Loss of function of <i>sul-2</i>, the <i>Caenorhabditis elegans</i> steroid sulfatase, elevates the pool of sulfated steroid hormones, increases longevity and ameliorates protein aggregation diseases. The present invention provides a group of molecules for use in the prevention of aging-associated proteotoxicity caused by protein aggregation diseases and/or to increase the lifespan of a eukaryotic organism. These molecules are either steroid sulfatase inhibitors or sulfated C19 steroids, both of which reproduce the phenotype of <i>sul-2</i> mutants. One particular representative example is STX-64. Potential applications of the claims have been demonstrated in animal models of Parkinson's disease, Huntington's disease and Alzheimer's disease.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"213-218"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10782412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent patents in the treatment and prevention of leishmaniasis. 治疗和预防利什曼病的最新专利。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-09-01 Epub Date: 2023-12-08 DOI: 10.4155/ppa-2023-0022
Sukhbir K Shahid
{"title":"Recent patents in the treatment and prevention of leishmaniasis.","authors":"Sukhbir K Shahid","doi":"10.4155/ppa-2023-0022","DOIUrl":"https://doi.org/10.4155/ppa-2023-0022","url":null,"abstract":"<p><p>Leishmaniasis, a neglected tropical disease, is caused by protozoal parasites of the genus <i>Leishmania</i>. Clinical manifestations vary from asymptomatic to lethal grade depending on the type of the disease. The currently available antileishmanial drugs suffer from considerable limitations. There is a dire need for better and safer drugs and/or vaccines to eradicate this disease. There are enormous developments ongoing in this field. Newer combinations of existing drugs and newer drugs targeting these intracellular parasites as well as their vectors are being tried to control the disease. Attempts to develop vaccines to enhance the immunity of the patient have shown some promise. This article is a peep into the recent patent developments in this field.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"12 5","pages":"237-248"},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138807301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights February-March 2023. 专利亮点2023年2月至3月。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-09-01 Epub Date: 2023-11-20 DOI: 10.4155/ppa-2023-0023
Hermann Am Mucke
{"title":"Patent highlights February-March 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0023","DOIUrl":"10.4155/ppa-2023-0023","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"205-212"},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug repurposing of rimantadine for treatment of cancer. 金刚乙胺治疗癌症的药物再利用。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-09-01 Epub Date: 2023-11-20 DOI: 10.4155/ppa-2023-0019
Nemesio Villa-Ruano, Vianey Marin-Cevada, Gabriela Sanchez-Esgua, Luis Villafaña-Diaz, Martin Perez-Santos
{"title":"Drug repurposing of rimantadine for treatment of cancer.","authors":"Nemesio Villa-Ruano, Vianey Marin-Cevada, Gabriela Sanchez-Esgua, Luis Villafaña-Diaz, Martin Perez-Santos","doi":"10.4155/ppa-2023-0019","DOIUrl":"10.4155/ppa-2023-0019","url":null,"abstract":"<p><p>Repurposing of approved drugs allows strong savings in time and investment. Rimantadine is an FDA-approved drug for prevention and treatment of influenza A infection. Patent US2021330605 describes the use of rimantadine, an adamantane derivative, for the treatment of melanoma, breast cancer and head and neck squamous cell carcinoma. Rimantadine inhibited proliferation of cell lines of melanoma, breast cancer, and head and neck squamous cell carcinoma, increased the survival of mice injected with cancer cell lines and restores the expression of MHC class I. Rimantadine has the potential to be used successfully in the treatment of head and neck squamous cell carcinoma.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"231-236"},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights December 2022-January 2023. 专利亮点2022年12月至2023年1月。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-07-01 Epub Date: 2023-10-06 DOI: 10.4155/ppa-2023-0016
Hermann Am Mucke
{"title":"Patent highlights December 2022-January 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0016","DOIUrl":"10.4155/ppa-2023-0016","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"151-158"},"PeriodicalIF":1.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41149760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent patent-based review on the role of three-dimensional printing technology in pharmaceutical and biomedical applications. 关于三维打印技术在制药和生物医学应用中的作用的最新专利综述。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-07-01 Epub Date: 2023-10-26 DOI: 10.4155/ppa-2023-0018
Palak Rani, Vikas Yadav, Parijat Pandey, Kiran Yadav
{"title":"Recent patent-based review on the role of three-dimensional printing technology in pharmaceutical and biomedical applications.","authors":"Palak Rani, Vikas Yadav, Parijat Pandey, Kiran Yadav","doi":"10.4155/ppa-2023-0018","DOIUrl":"10.4155/ppa-2023-0018","url":null,"abstract":"<p><p>Three-dimensional printing (3DP) is emerging as an innovative manufacturing technology for biomedical and pharmaceutical applications, since the US FDA approval of Spritam as a 3D-printed drug. In the present review, we have highlighted the potential benefits of 3DP technology in healthcare, such as the ability to create patient-specific medical devices and implants, as well as the possibility of on-demand production of drugs and personalized dosage forms. We have further discussed future research to optimize 3DP processes and materials for pharmaceutical and biomedical applications. Cohesively, we have put forward the current state of active patents and applications related to 3DP technology in the healthcare and pharmaceutical industries including hearing aids, prostheses, medical devices and drug-delivery systems.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"159-175"},"PeriodicalIF":1.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50162460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic charisma of imidazo [2,1-b] [1,3,4]-thiadiazole analogues: a patent review. 咪唑 [2,1-b] [1,3,4]- 噻二唑类似物的治疗魅力：专利回顾。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-07-01 Epub Date: 2023-09-06 DOI: 10.4155/ppa-2023-0006
Anuradha Mehra, Rekha Sangwan, Aryan Mehra, Shivani Sharma, Pankaj Wadhwa, Amit Mittal
{"title":"Therapeutic charisma of imidazo [2,1-b] [1,3,4]-thiadiazole analogues: a patent review.","authors":"Anuradha Mehra, Rekha Sangwan, Aryan Mehra, Shivani Sharma, Pankaj Wadhwa, Amit Mittal","doi":"10.4155/ppa-2023-0006","DOIUrl":"10.4155/ppa-2023-0006","url":null,"abstract":"<p><p>Imidazothiadiazole was discovered around the 1950s era, containing an imidazole ring fused to a thiadiazole ring. Imidazothiadiazole exhibit versatile pharmacological properties including anticonvulsant, cardiotonic, anti-inflammatory, diuretic, antifungal, antibacterial and anticancer. Despite of the being discovered in 1950s, the imidazothiadiazole derivatives are unable to being processed to clinical trials because of lack of bioavailability, efficacy and cytotoxicity. The recent patent literature focused on structural modification of imidazothiadiazole core to overcome these problems. This review limelight a disease-centric perspective on patented imidazothiadiazole from 2015-2023 and to understand their mechanism of action in related diseases. The relevant granted patent applications were located using patent databases, Google Patents, USPTO, EPO, WIPO, Espacenet and Lens.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"177-191"},"PeriodicalIF":1.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10164946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信